Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Non-Current Debt of $609.8 million for Q1 2026, up 0.98% year-over-year from $603.9 million in Q1 2025, and little changed quarter-over-quarter from $608.7 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Non-Current Debt history runs 14 years deep, the most recent figure standing at $609.8 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 0.98% year-over-year to $609.8 million; the TTM figure through Mar 2026 stood at $609.8 million (up 0.98% YoY), while the FY2025 annual figure was $608.7 million, up 1.18% from the prior year.
- Non-Current Debt for Q1 2026 stood at $609.8 million, roughly flat from $608.7 million in the prior quarter.
- The five-year high for Non-Current Debt was $638.2 million in Q3 2023, with the low at $72.8 million in Q4 2022.
- The 5-year median for Non-Current Debt is $594.0 million (2024), against an average of $441.3 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt jumped 762.31% in 2023, then dropped 6.54% in 2024.
- Amphastar Pharmaceuticals' Non-Current Debt stood at $72.8 million in 2022, then jumped by 709.43% to $589.6 million in 2023, then gained by 2.04% to $601.6 million in 2024, then gained by 1.18% to $608.7 million in 2025, then rose by 0.17% to $609.8 million in 2026.
- Business Quant data shows AMPH's Non-Current Debt at $609.8 million in Q1 2026, $608.7 million in Q4 2025, and $608.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Amphastar Pharmaceuticals | 943.15 Mn | 653.02 Mn | 93.47 Mn | 609.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 609.56 Mn |
| Mar 31, 2026 | 609.80 Mn |
| Dec 31, 2025 | 608.75 Mn |
| Sep 30, 2025 | 608.58 Mn |
| Jun 30, 2025 | 607.73 Mn |
| Mar 31, 2025 | 603.86 Mn |
| Dec 31, 2024 | 601.63 Mn |
| Sep 30, 2024 | 596.45 Mn |
| Jun 30, 2024 | 586.85 Mn |
| Mar 31, 2024 | 594.01 Mn |
| Dec 31, 2023 | 589.58 Mn |
| Sep 30, 2023 | 638.21 Mn |
| Jun 30, 2023 | 488.28 Mn |
| Mar 31, 2023 | 72.87 Mn |
| Dec 31, 2022 | 72.84 Mn |
| Sep 30, 2022 | 74.01 Mn |
| Jun 30, 2022 | 73.87 Mn |
| Mar 31, 2022 | 74.35 Mn |
| Dec 31, 2021 | 74.78 Mn |
| Sep 30, 2021 | 75.55 Mn |